InterCure, Ltd. Announces Launch of RESPeRATE Ultra
11/18/2008 11:28:59 AM
NEW YORK--(BUSINESS WIRE)--InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced the U.S. release of its next generation hypertension treatment device, RESPeRATE Ultra. The new product, which incorporates new interactive features and a simpler user experience in just half the size of previous models, will be initially sold through www.resperate.com at a price of $349.95.